Popular Trials
Tyrosine Kinase Inhibitor
Imatinib or Dasatinib for Chronic Myeloid Leukemia
Recruiting1 awardPhase 2
Burbank, California
This trial looks at two different doses of imatinib mesylate and dasatinib to see how well they work in treating patients with previously untreated chronic phase chronic myelogenous leukemia.
Senolytic Agent
Senolytic Therapy for Chronic Kidney Disease
Recruiting1 awardPhase 2
Rochester, Minnesota
This trial will test whether getting rid of senescent cells can help people with chronic kidney disease by reducing senescence burden, improving physical ability or frailty, and increasing mesenchymal stem cell functionality.
Popular Filters
Phase 3 Trials
Corticosteroid
Chemotherapy Regimen for Acute Lymphoblastic Leukemia
Recruiting2 awardsPhase 3
Boston, Massachusetts
This trial is studying a new way to treat acute lymphoblastic leukemia (ALL). The new way involves using a new, updated set of risk factors to decide how strong the treatment will be and testing a new way of dosing a chemotherapy drug.
Anti-tumor antibiotic
Chemotherapy for Acute Lymphoblastic Leukemia
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial will study combination chemotherapy in young patients with newly diagnosed B acute lymphoblastic leukemia that is likely to come back or spread, and in patients with Philadelphia chromosome (Ph)-like tyrosine kinase inhibitor (TKI) sensitive mutations.
Chemotherapy
Total Therapy XVII for Leukemia
Recruiting1 awardPhase 2 & 3
Palo Alto, California
This trial is using novel precision medicine strategies based on inherited and acquired leukemia-specific genomic features and targeted treatment approaches to improve the cure rate and quality of life of children with acute lymphoblastic leukemia (ALL) and acute lymphoblastic lymphoma (LLy).
Tyrosine Kinase Inhibitor
Asciminib vs Other TKIs for Chronic Myeloid Leukemia
Recruiting2 awardsPhase 3
Greenwood Village, Colorado
This trial is testing a new drug called asciminib against other existing treatments for adults newly diagnosed with a specific type of leukemia. The goal is to see if asciminib is more effective at blocking a protein that helps cancer cells grow. Asciminib has shown superior efficacy in patients with chronic myeloid leukemia (CML) previously treated with multiple other treatments.
Senolytic
Dasatinib + Quercetin for Obesity
Recruiting0 awardsPhase 2 & 3
Los Angeles, California
This trial will involve taking samples of fat tissue from the abdomen of all participants to study their cells and molecules. The participants will also undergo tests to measure their insulin sensitivity, glucose tolerance, and function of
Trials With No Placebo
Monoclonal Antibodies
Blinatumomab + Chemotherapy/Dasatinib for Acute Lymphoblastic Leukemia
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial is studying the side effects and efficacy of blinatumomab and combination chemotherapy or dasatinib and prednisone in treating older patients with acute lymphoblastic leukemia.
mTOR Inhibitor
Everolimus +5 More for Pediatric Brain Tumor
Recruiting3 awards10 criteria
Seattle, Washington
This research study is a Feasibility clinical trial. In this trial, researchers are trying to figure out whether a medication can be chosen based on rapid testing done on tumor tissue. Information from a feasibility or pilot trial will hopefully help researchers plan larger trials in the future to determine the effect of this therapy.
Corticosteroid
Prednisone +1 More for Prostate Cancer
Recruiting3 awardsPhase 2
Los Angeles, California
This phase II trial studies how well giving abiraterone acetate and prednisone with or without dasatinib works in treating patients with metastatic, hormone-resistant prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as abiraterone acetate, may lessen the amount of androgens made by the body. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether abiraterone acetate and prednisone is more effective than abiraterone acetate, prednisone, and dasatinib in treating prostate cancer
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.